Current Clinical Trials in Asthma, Chronic Obstructive Pulmonary Disease(COPD), Cystic Fibrosis, Pulmonary Arterial Hypertension (PAH) and Idiopathic Pulmonary Fibrosis
|
|
This is an observational, prospective study of preterm infants 32 to 35 wGA. Subjects will be screened and entered into the study during their earliest pediatric outpatient visit (routine well-baby visit or unscheduled sick visit), from 01Sep2009 through 31Jan2010 for Season 1, and from 01Sep2010 through 31Jan2011 for Season 2. All subjects will be followed up to the end of their first RSV season (31May). Interval (between-visit) RSV infections, hospitalizations, ED visits, and outpatient LRIs will be assessed during each follow-up visit between the Initial Visit and 31May. When an interval event is reported, medical records/charts will be obtained by the investigator to collect all study-pertinent information, including any RSV testing and results.
|
|
This trial is a randomized, double-blind, parallel-group, multicenter study to be conducted in the United States. The purpose of the study is to evaluate the rate of exacerbations of chronic obstructive pulmonary disease (COPD) following hospital discharge for an acute exacerbation of COPD, in patients receiving either fluticasone propionate/salmeterol combination product 250/50mcg BID or salmeterol 50mcg BID via DISKUS™ over 29 weeks. The study population will include patients hospitalized for an acute exacerbation of COPD |
|
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period. This study is evaluating both children 12- 17 years of age and adults. |
|
One Year Study – Study No. AC-063A406
A multicenter, retrospective study of patients with pulmonary arterial hypertension receiving inhaled iloprost for ≥ year |
- This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy to high-dose ICS+LABA for the treatment of subjects aged 12-75 years old diagnosed with moderate to severe asthma who are inadequately controlled with high-dose ICS+LABA.
|
- To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.
|
|
The purpose of this study is to assess the comparative safety and effectiveness of Aztreonam for Inhalation Solution versus Tobramycin Nebuliser Solution in adult and pediatric patients with CF and pulmonary Pseudomonas aeruginosa (PA) infection. |
|
A randomised multicenter study comparing the effect on time to
clinical failure of initial combination therapy (ambrisentan and
tadalafil) and initial monotherapy (ambrisentan or tadalafil) in
subjects with pulmonary arterial hypertension.
|
- The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
|
- This study will assess efficacy and safety of indacaterol (150 µg once daily [o.d.]) when combined with tiotropium (18 µg o.d.) versus tiotropium (18 µg o.d.) treatment alone in patients with chronic obstructive pulmonary disease (COPD)
|
- This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations
- For adults 18 years of age and greater
|
|
The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months. Patients diagnosed with WHO Group I PAH who are on a stable regimen of commercial Ventavis® will be followed for a maximum of 2 years from the time of enrollment. Data will be collected via patient interview and review of the medical record. Quarterly data collection will include capture of medications and Ventavis® adherence data. |
- The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
|
- This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations.
- For Children up to 18 years of age.
|
- A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the I-Neb® AAD®Adult Patients
|
- This study will assess the effect of pancrelipase delayed release 24,000 unit capsules on fat and nitrogen absorption in subjects with PEI due to Cystic Fibrosis.
|
- A major factor in the respiratory health of CF subjects is acquisition of chronic Pseudomonas aeruginosa infections. The infection rate with P. aeruginosa increases with age and by age 18 years, 80% of CF subjects in the U.S. are infected. Liposomal Amikacin for Inhalation (ArikaceTM) is a sustained-release formulation of amikacin encapsulated inside nanoscale liposomal carriers designed for administration via inhalation. It is hypothesized that the sustained-release pulmonary targeting and biofilm penetration properties of this formulation will have several advantages over current therapies in treating CF subjects with chronic infection caused by P. aeruginosa.
|
- The purpose of this study is to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis (CF) patients with clinical symptoms of exocrine pancreatic insufficiency (EPI).
|
|
|
|
|
